Table 1.
Study Cohort.
| Parameter | Study Cohort |
|---|---|
| CCA patients | n = 75 |
| Gender (%): | |
| male | 53.3 (40) |
| female | 46.7 (35) |
| Age (years, median, and range) | 70 (30–87) |
| BMI class (kg/m2, %) | |
| BMI < 20 | 9.3 (7) |
| BMI 20–25 | 45.3 (34) |
| BMI 25–30 | 28 (21) |
| BMI > 30 | 17.3 (13) |
| Systemic therapy (%) | |
| Yes | 85.3 (64) |
| No | 14.7 (11) |
| Chemotherapy regimen (%) | |
| Gemcitabine + Cisplatin | 81.3 (52) |
| Gemcitabine + Oxaliplatin | 4.7 (3) |
| Carboplatin + Paclitaxel | 1.6 (1) |
| Capecitabine Mono | 1.6 (1) |
| Gemcitabine Mono | 10.9 (7) |
| Tumor progression during follow-up? (%) | |
| Yes | 28 (21) |
| No | 72 (54) |
| Localization of tumor metastasis (%) | |
| Lymphatic | 20 (15) |
| Vascular | 8 (6) |
| Pulmonary | 18.7 (14) |
| Bone | 10.7 (8) |
| Suprarenal gland | 1.3 (1) |
| Peritoneum | 22.7 (17) |
| Other | 16 (12) |
| Pre-existing medical conditions (%) | |
| Preceded tumor disease | 24 (18) |
| Preceded systemic chemotherapy | 1.3 (1) |
| Diabetes mell. Typ 2 | 29.3 (22) |
| Arterial hypertension | 58.7 (44) |
| Hepatitis B | 6.7 (5) |
| Hepatitis C | 5.3 (4) |
| Alcohol abuse | 1.3 (1) |
| Primary biliary cholangitis | 2.7 (2) |
| Primary sclerosing cholangitis | 1.3 (1) |
| Nonalcoholic steatohepatitis | 2.7 (2) |
| Inflammatory bowel disease | 1.3 (1) |
| Gastritis | 24 (18) |
| Overall survival (days, median, and range) | 224 (3–1059) |
| Progression-free survival (days, median, and range) | 132 (3–916) |
| Bone mineral density (HU, median, and range) | 144 (57.65–258) |
| AFP (mean, range) | 1025.5 (1.0–31,496) ng/mL (49) |
| CEA (mean, range) | 38.8 (0.7–653.5) ng/mL (54) |
| Ca19-9 (mean, range) | 1584.8 (0.6–10,000) U/mL (56) |
BMI: Body mass index; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; table modified after [4].